Nuveen
CRDF icon

Nuveen’s Cardiff Oncology CRDF Stock Holding History

Nuveen’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-130,346
Closed -$211K – 3757
2026
Q1 		$211K Buy
130,346
+50,126
+62% +$103K ﹤0.01% 3083
2025
Q4 		$225K Sell
80,220
-114,090
-59% -$265K ﹤0.01% 3114
2025
Q3 		$400K Sell
194,310
-365,959
-65% -$1.01M ﹤0.01% 2976
2025
Q2 		$1.76M Sell
560,269
-297,301
-35% -$907K ﹤0.01% 2359
2025
Q1 		$2.69M Buy
857,570
+270,954
+46% +$1.07M ﹤0.01% 2208
2024
Q4 		$2.55M Buy
586,616
+248,850
+74% +$778K ﹤0.01% 2281
2024
Q3 		$902K Buy
337,766
+284,650
+536% +$672K ﹤0.01% 2806
2024
Q2 		$118K Buy
+53,116
New +$200K ﹤0.01% 3297
2022
Q2 		– Sell
-249,912
Closed -$595K – 3289
2022
Q1 		$595K Sell
249,912
-102,755
-29% -$363K ﹤0.01% 2963
2021
Q4 		$1.88M Buy
352,667
+116,890
+50% +$697K ﹤0.01% 2592
2021
Q3 		$1.62M Buy
235,777
+41,536
+21% +$261K ﹤0.01% 2772
2021
Q2 		$1.29M Buy
+194,241
New +$1.65M ﹤0.01% 2907

Other funds holding CRDF

LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Nuveen's CRDF Position: Q2 2026 in Review

Nuveen sold out of Cardiff Oncology (CRDF) in Q2 2026, closing a stake of 130,346 shares — an estimated $211K sold.

Nuveen first reported a position in CRDF in Q2 2021 and held it in 12 quarters. The position peaked at $2.69M in Q1 2025. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

  • Nuveen reported no remaining Cardiff Oncology position as of Q2 2026 after selling out during the quarter.
  • Nuveen sold 130,346 Cardiff Oncology shares in Q2 2026, an estimated $211K.
  • Nuveen first reported a position in Cardiff Oncology in Q2 2021 and held it in 12 quarters.
  • Nuveen's Cardiff Oncology position peaked at $2.69M in Q1 2025.
  • 105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.